Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

Stemline Investors Reminder: Hagens Berman Reminds

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
(Total Views: 120)
Posted On: 03/17/2017 5:00:19 PM
Avatar
Posted By: News Desk 2018
Stemline Investors Reminder: Hagens Berman Reminds Investors in Stemline Therapeutics of the April 4, 2017 Lead Plaintiff Deadline

SAN FRANCISCO, March 17, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Stemline Therapeutics, Inc. (NASDAQ: STML ) of the April 4, 2017 Lead Plaintiff deadline in the pending securities class action.

If you purchased or otherwise acquired securities of Stemline (1) pursuant to Stemline’s secondary public offering on or about January 20, 2017 or (2) on the open market between January 6, 2017 and February 1, 2017  and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:

https://www.hbsslaw.com/cases/STML

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing STML@hbsslaw.com .

On February 2, 2017, TheStreet published an article entitled “Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money.”  TheStreet reported that investors who bought into a $45 million Stemline Therapeutics stock offering on January 19, 2017 were not told that one day prior to the financing, a cancer patient in a clinical trial died from a severe side effect, a type of low blood pressure, tied to the Company’s SL-401 drug.

This news drove the price of Stemline shares down over 42% on February 2, 2017.

“A cancer patient’s death occurring from Stemline SL-401 related side effects is a tragic event and is a fact reasonable investors would want to know about,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Stemline should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email STML@hbsslaw.com .

About Hagens Berman Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com .  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw .

Contact: Reed Kathrein, 510-725-3000



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us